Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: bob beck who wrote (2681)	7/13/1999 7:51:00 AM
From: CUBBY	Read Replies (2) \| Respond to of 4140

FDA Approval for Same Day SecondEye Treatment for Sunrise Technologies LTK Mid-hyperopia Study --+2.75 to +4.0 Diopters July 13, 1999 07:04 AM FREMONT, Calif.--(BW HealthWire)--July 13, 1999--Sunrise Technologies International, Inc. SNRS announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to treat, in its ongoing U.S. clinical trials, the second eye on the same day as the first eye using the Sunrise laser thermal keratoplasty (LTK) treatment for mid-hyperopia from +2.75 to +4.0 diopters. The approval allows for treatment of the second eye of the current subjects as well as treatment of both eyes of future subjects on the same day. On May 4, Sunrise announced it had received approval from the FDA to expand its study for the treatment of mid-hyperopia. The study was expanded to 80 patients at up to six clinical investigation sites in the United States. Twenty patients at two sites have already been treated under a study that began in April 1998. Sunrise LTK surgeons and patients reported that they were eager to have immediate treatment of the second eye after receiving initial treatment. The Company estimates that the ability to treat up to 4 diopters of hyperopia represents nearly 90% of all hyperopes over the age of 40. The technique for treating mid-hyperopia utilizes the same laser as that which is used in the Company's initial study for treatment of hyperopia from +.75 to +2.5 diopters. Two rings of sixteen spots of laser energy are applied to the mid periphery of the cornea at the six and seven millimeter zones. Similarly, the technique for the study for lower levels of hyperopia (+.75 to +2.5 diopters) undergoing PMA review applies two rings of eight spots of laser energy at the six millimeter and seven millimeter zones at the mid periphery of the cornea. Each ring of eight spots of energy is applied in 1.4 seconds and gently heats collagen in the cornea to change corneal shape. The application of energy is accomplished without physically contacting the cornea with instrumentation or any other apparatus. The patient sits upright opposite the ophthalmic surgeon and the total chair time, including focusing, is designed to be less than five minutes. The conditional approval means that the FDA has requested the Company submit additional information to the agency within 15 days which the Company has agreed to do. Founded in 1987, the Company produces and markets high technology products revolutionizing treatment methods in eye care. The Company develops Holmium laser-based systems, which utilize a patented process for shrinking collagen developed by Dr. Bruce Sand (the "Sand Process") in correcting ophthalmic conditions. These Systems(a) incorporate a non-contact simultaneous application for correction of hyperopia (farsightedness), presbyopia (loss of focus due to natural aging), and overcorrection resulting from PRK and LASIK treatments for myopia. The system is currently in use in Europe and the Americas, and is in clinical trials in the United States. Except for historical information, this news release contains certain forward-looking statements that involve risk and uncertainties which may cause actual results to differ materially from the statements made, including market potential, regulatory clearances, business growth, and other risks listed from time to time in the Company's Securities and Exchange Commission (SEC) filings. These forward-looking statements represent the Company's judgement, as of the date of this release, and the Company disclaims any intent or obligation to update these forward-looking statements. (a) Caution-Investigational Device: Federal law restricts this device to investigational use in the U.S. Internet users can access Sunrise's World Wide Web site at sunrise-tech.com. CUBBY

To: bob beck who wrote (2681)	7/13/1999 11:23:00 AM
From: BARRY ALLEN	Respond to of 4140

90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% 90% The Company estimates that the ability to treat up to 4 diopters of hyperopia represents nearly 90% of all hyperopes* over the age of 40.* Sturza = Turdza! Still, Sturza's Medical Research analyst Stephen Sabba remains critical of the device, noting that the low levels of hyperopia that it has treated in its studies. He maintains the narrow range of diopters that the device can treat won't produce a significant demand for the product. Sturza's Institutional Research provides independent, unbiased medical technology assesments on a soft-dollar basis. These assessments are supplemented by our consulting arrangements with more than 600 clinical researchers at many of the leading research centers in the United States. July 13, 1999 07:04 AM FREMONT, Calif.--(BW HealthWire)--July 13, 1999--Sunrise Technologies International, Inc. SNRS announced that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to treat, in its ongoing U.S. clinical trials, the second eye on the same day as the first eye using the Sunrise laser thermal keratoplasty (LTK) treatment for mid-hyperopia from +2.75 to +4.0 diopters. The Company estimates that the ability to treat up to 4 diopters of hyperopia represents nearly 90% of all hyperopes over the age of 40. Maybe we should contact Sturza and Avalon so they could inform their 600 clinical researchers at many of the leading research centers in the United States! info@sturzas.com research@avalonresearch.com

To: bob beck who wrote (2681)	7/13/1999 8:56:00 PM
From: BARRY ALLEN	Read Replies (1) \| Respond to of 4140

1.6 million shares short in June!! Bye, bye Avalon(AVLN)! Thanks for the opportunities. Hope you didn't cover yet so you can help drive SNRS higher! Wonder what your clients are thinking now! TOTAL VOLUME AVLN - AVALON RESEARCH GROUP, INC. Legend: M - Market Maker, N - Non-registered Market Maker, E - ECN MP June 1999 May 1999 Year to Date Type Volume Rank % Volume Rank % Volume Rank % -------------------------------------------------------------------------------- Total Volume 4,645,240 4,020,758 21,756,759 -------------------------------------------------------------------------------- SNRS M 1,606,071 3 7 - - - 1,606,071 16 1 CBMI M 715,375 4 10 639,331 3 11 2,053,682 6 7 ESTI M 473,140 4 10 75,700 10 3 2,486,305 4 9 LNCR M 407,079 8 3 1,299,623 3 12 2,894,326 7 4 CLTR M 341,400 5 7 6,000 23 <1 757,300 9 3 ENZN M 178,900 12 2 59,000 14 1 418,300 19 1 CLPA M 177,800 8 3 138,900 11 2 1,487,565 9 3 MCHM M 168,000 11 2 10,300 24 <1 548,000 13 2 nasdaqtrader.com